Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.

This study is an open, multicenter, phase II clinical study for evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ALK202 for injection combined with different drugs in participants with locally advanced or metastatic NSCLC. The study consists of two phases: the Phase IIa (dose escalation) and the Phase IIb (efficacy extension). Phase IIa (dose escalation) :This stage consists of 3 cohorts, which will respectively recruit participants meeting the criteria for each cohort who have locally advanced or metastatic NSCLC, to complete the dose escalation for each combination regimen. The Escalation cohort 1: participants with locally advanced or metastatic EGFR mutation (EGFRmut) non-squamous NSCLC who have failed previous EGFR-TKI treatment, and they will receive ALK202 combined with Osimertinib Mesylate Tablets. The Escalation cohort 2: participants with locally advanced or metastatic EGFR wild-type (EGFRwt) NSCLC who have failed previous standard treatment, and they will receive ALK202 combined with Ivonescimab Injection. The Escalation cohort 3: participants with locally advanced or metastatic EGFRwt NSCLC who have failed previous standard treatment, and they will receive ALK202 combined with Ivonescimab Injection and Carboplatin Injection. Phase IIb (Efficacy Extension ) In this phase, three cohorts are initially planned. They will respectively recruit participants with locally advanced or metastatic NSCLC who meet the criteria of each combination regimen, to evaluate the efficacy of ALK202 combined with different drugs, and further assess its safety. Extension Cohort 1:participants with EGFRmut non-squamous NSCLC that has not received systemic palliative treatment; Extension Cohort 2: participants with NSCLC driver gene negative NSCLC and PD-L1 expression ≥ 1% and high c-MET expression that has not received systemic treatment; Extension Cohort 3: participants with NSCLC driver gene negative NSCLC and PD-L1 expression \< 1% and high c-MET expression that has not received systemic treatment. Expansion cohort 1: two groups participants treated with ALK202 at two different doses in combination with Osimertinib Mesylate Tablets. Eachdose group enrolled 30 trial participants, totaling 60 participants, and they are randomly assigned in a 1:1 ratio. The ALK202 treatment regimen involves intravenous infusion, on Day 1 or on Days 1 and 8, every 3 weeks or twice, until disease progression, intolerability, or death occurs. The Osimertinib Mesylate Tablets treatment regimen is 80 mg, orally, once daily, until disease progression, intolerability, or death. Expansion cohort 2: two groups participants treated with ALK202 at two different doses in combination with Ivonescimab Injection. Each dose group includes 30 participants, totaling 60 participants, and they are randomly assigned in a 1:1 ratio. The ALK202 treatment regimen involves intravenous infusion, on Day 1 or on Days 1 and 8, every 3 weeks or twice. Until the disease progresses or becomes intolerable or leads to death; the Ivonescimab Injection treatment regimen is 20 mg/kg, administered intravenously, once every 3 weeks, until the disease progresses or becomes intolerable or leads to death. Expansion cohort 3: participants will select two dosing regimens from the two-drug combination of ALK202+Ivonescimab Injection or the three-drug combination of ALK202 +Ivonescimab Injection+ Carboplatin for exploration based on the preliminary safety and efficacy results of ascending cohort 2 and ascending cohort 3.